ARYA Sciences Acquisition Corp II
Status: Deal Closed
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $149.50M |
|---|---|
| IPO Date | Jun 5, 2020 |
| CEO | Adam Stone |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Life sciences and medical technologies in North America and Europe |
| IPO Geography | Global |
| Target Company | Cerevel Therapeutics |
| Deal Announced | Jul 30, 2020 |
| Deal Size, $M | $847.37M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Oct 26, 2020 |
| Amendment Vote | TBD |
| Closing Date | Oct 27, 2020 |
Formerly ARYB
CERE
CEREW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on ARYA Sciences Acquisition Corp II:
- Structure and cap table
- 7 directors & officers
- 21 filings and events
- 2 underwriters
- 7 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Joseph Edelman | 64 | Chairman |
| Adam Stone | 40 | CEO and Director |
| Michael Altman | 38 | CFO and Director |
| Konstantin Poukalov | 36 | Chief Business Officer |
| Jake Bauer | 41 | Director |
| Dr. Todd Wider | 55 | Director |
| Chad Robins | 46 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Jefferies | Joint BR | 6,500,000 | units |
| Goldman Sachs | Joint BR | 6,500,000 | |
| 13,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.